Fleury Herve, Tumiotto Camille, Bellecave Pantxika, Recordon-Pinson Patricia
Laboratoire de Virologie, CHU de Bordeaux et CNRS UMR 5234, Université de Bordeaux , Bordeaux, France .
AIDS Res Hum Retroviruses. 2018 Jan;34(1):27-30. doi: 10.1089/aid.2017.0175. Epub 2017 Oct 12.
The scientific and medical community is seeking to cure HIV. Several pathways have been or are being explored including therapeutic vaccination. Viroimmunological studies on primary infection as well as on elite controllers have demonstrated the importance of the cytotoxic CD8 response and have mainly oriented research on vaccine constructs toward this type of response. The results of these trials are clearly not commensurate with the hope placed in them. Might there be one or more uncontrolled variables? The genetics of patients need to be taken into consideration, especially their human lymphocyte antigen (HLA) alleles. There is a need to find a balance between the conservation of cytotoxic T lymphocyte (CTL) epitopes and presentation by HLA alleles. The pathway is a narrow one between adaptation of the virus to HLA I restriction and the definition of conserved proviral CTL epitopes presentable by HLA I alleles. It is likely that the genetics of patients will need to be considered for HIV-1 vaccine studies and that multidisciplinary collaboration will be essential in this field of infectious diseases.
科学界和医学界正在寻求治愈艾滋病病毒的方法。已经或正在探索多种途径，包括治疗性疫苗接种。对初次感染以及精英控制者的病毒免疫学研究表明了细胞毒性CD8反应的重要性，并主要将疫苗构建体的研究导向了这类反应。这些试验的结果显然与人们寄予它们的希望不相称。是否存在一个或多个未得到控制的变量呢？需要考虑患者的遗传学因素，尤其是他们的人类淋巴细胞抗原（HLA）等位基因。有必要在细胞毒性T淋巴细胞（CTL）表位的保守性与HLA等位基因的呈递之间找到平衡。在病毒适应HLA I类限制与定义可由HLA I类等位基因呈递的保守前病毒CTL表位之间，这条路很窄。在HIV-1疫苗研究中，很可能需要考虑患者的遗传学因素，并且多学科合作在这个传染病领域将至关重要。
